OTC Derivatives Regulation: Sorting Out The Processes -- Webcast

While electronification of OTC derivatives last year appeared to go smoothly, problems lingered concerning collateral and reporting, along with discrepancies in the rules for swaps and swap futures that needed to be addressed. This webcast sorted through confusing parts of new rules and guidelines for OTC derivatives reporting, as well as their possible results – data quality issues and data integrity problems.

How have EMIR reporting rules affected the OTC derivatives reporting process?

• How may ESMA’s [European Securities and Markets Authority] systems development review plans proceed? How long will it take to implement improvements?
• Do US and North American markets have the same issues with responding to CFTC rules as Europeans have with EMIR and ESMA actions? How do these compare?
• What data quality and integrity issues are arising in efforts to comply with OTC derivatives reporting rules?
• What parts of the rules and guidelines remain confusing and how may those be addressed?

Moderator: Michael Shashoua, Editor, INSIDE REFERENCE DATA

• Judson Baker, Senior Vice President, NORTHERN TRUST CORPORATION
• Neil Monaghan, Global Head of OTC Clearing Client Solutions, CITI GROUP
• Cristiano Zazzara, Vice President, EMEA Head of Application Specialists, S&P CAPITAL IQ